Editor Profile

David H. Ilson, MD, PhD

Associate Editor

About the NEJM Watch Oncology and Hematology Board

Dr. Ilson completed undergraduate training at the University of Connecticut. He entered an MD, PhD combined degree program at New York University and received a Master’s degree and PhD in Basic Science and an MD from New York University. He completed his internship and residency in internal medicine at Bellevue Hospital at NYU in New York. He then moved to Memorial Sloan-Kettering Cancer Center and completed a fellowship in medical oncology and hematology, including a third-year fellowship as the Brian Piccolo research fellow. He joined the staff at MSKCC in 1992, becoming a member of the GI Oncology Service in the Department of Medicine. He was a recipient of an American Cancer Society Career Development Award. Dr. Ilson is now an attending physician and member at Memorial Hospital and is professor of medicine at Weill-Cornell Medical College. His area of research interest is upper gastrointestinal cancer with a focus on esophageal cancer. He is a nationally recognized authority in the treatment of gastrointestinal cancer. His research has focused on the study of new agents in advanced esophageal cancer and on the evaluation of novel agents in combined modality therapy programs in locally advanced disease. He sits on the GI committees of Cancer and Leukemia Group B (CALGB) and Radiation Therapy Oncology Group (RTOG) as well as the Upper GI Cancer Guidelines Committee of the National Comprehensive Cancer Network (NCCN). He is chairman on the Intergroup Esophageal and Gastric Cancer Task Force Committee. He currently chairs or co-chairs several national clinical trials in esophageal cancer. Dr. Ilson has been writing for NEJM Journal Watch Oncology and Hematology since 2006.


Consultant / Advisory board

Amgen; Eli Lilly–ImClone; Bayer; Merck; Bristol-Myers Squibb; Roche-Genentech; Pieris; Astellas